Abstract
Surgery, radiation therapy, and chemotherapy are the traditional options to control tumor progression. However, these strategies are fraught with harmful side effects and are ineffective in metastatic and advanced cancers. Biomarkers that are overexpressed in cancers and are involved in cell growth, proliferation, migration, and survival have recently become the focus of new molecular targeting therapies. Novel therapies targeting biomarkers have roles in tumorigenesis that are overexpressed in cancers may be more efficacious and less toxic in comparison to traditional therapies. These therapies include the use of tyrosine kinase inhibitors and monoclonal antibodies for the treatment of cancer. However, the efficacy of these therapies is limited due to the development of drug resistance after prolonged treatment. Current research is focused on understanding mechanisms of resistance to overcome the barriers limiting the use of these targeting therapies in the treatment of cancer. In this review, we will discuss the clinical status of tyrosine kinase inhibitors and monoclonal antibodies against several prevalent biomarkers that are candidates for therapy in non-small cell lung cancer (NSCLC) and melanoma.
Keywords: Melanoma, monoclonal antibodies, NSCLC, tyrosine kinase inhibitor.
Anti-Cancer Agents in Medicinal Chemistry
Title:Current Molecularly Targeting Therapies in NSCLC and Melanoma
Volume: 15 Issue: 7
Author(s): Supriya Rajanna, Ichwaku Rastogi, Luke Wojdyla, Hiroko Furo, Agnes Kulesza, Leo Lin, Bonnie Sheu, Mark rakes, Marko Ivanovich and Neelu Puri
Affiliation:
Keywords: Melanoma, monoclonal antibodies, NSCLC, tyrosine kinase inhibitor.
Abstract: Surgery, radiation therapy, and chemotherapy are the traditional options to control tumor progression. However, these strategies are fraught with harmful side effects and are ineffective in metastatic and advanced cancers. Biomarkers that are overexpressed in cancers and are involved in cell growth, proliferation, migration, and survival have recently become the focus of new molecular targeting therapies. Novel therapies targeting biomarkers have roles in tumorigenesis that are overexpressed in cancers may be more efficacious and less toxic in comparison to traditional therapies. These therapies include the use of tyrosine kinase inhibitors and monoclonal antibodies for the treatment of cancer. However, the efficacy of these therapies is limited due to the development of drug resistance after prolonged treatment. Current research is focused on understanding mechanisms of resistance to overcome the barriers limiting the use of these targeting therapies in the treatment of cancer. In this review, we will discuss the clinical status of tyrosine kinase inhibitors and monoclonal antibodies against several prevalent biomarkers that are candidates for therapy in non-small cell lung cancer (NSCLC) and melanoma.
Export Options
About this article
Cite this article as:
Rajanna Supriya, Rastogi Ichwaku, Wojdyla Luke, Furo Hiroko, Kulesza Agnes, Lin Leo, Sheu Bonnie, rakes Mark, Ivanovich Marko and Puri Neelu, Current Molecularly Targeting Therapies in NSCLC and Melanoma, Anti-Cancer Agents in Medicinal Chemistry 2015; 15 (7) . https://dx.doi.org/10.2174/1871520615666150202100130
DOI https://dx.doi.org/10.2174/1871520615666150202100130 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhibitors of 11β-Hydroxylase (CYP11B1) for Treating Diseases Related to Excess Cortisol
Current Medicinal Chemistry Synergistic Activity of the c-Met and Tubulin Inhibitor Tivantinib (ARQ197) with Pemetrexed in Mesothelioma Cells
Current Drug Targets Novel Therapeutic Approaches to Autoimmune Demyelinating Disorders
Current Pharmaceutical Design The ErbB Receptors and their Ligands in Cancer: An Overview
Current Drug Targets Biomarkers to Assess the Targeting of DNA Repair Pathways to Augment Tumor Response to Therapy
Current Molecular Medicine Role of Pemetrexed and Platinums Combination in Patients with Non- Small Cell Lung Cancer
Current Drug Targets The MYC Oncogene as a Cancer Drug Target
Current Cancer Drug Targets Pathophysiological Functions of the lncRNA TUG1
Current Pharmaceutical Design Synthesis and Biological Evaluation of Scutellaria Flavone Cyclaneaminol Mannich Base Derivatives as Novel CDK1 Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Emerging Roles of microRNAs in the Molecular Responses to Hypoxia
Current Pharmaceutical Design Overview of Base Excision Repair Biochemistry
Current Molecular Pharmacology Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer
Current Cancer Drug Targets Tumor Protein p63/microRNA Network in Epithelial Cancer Cells
Current Genomics T Cell Polarization and the Formation of Immunological Synapses: From Antigen Recognition to Virus Spread
Current Immunology Reviews (Discontinued) The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development
Current Molecular Medicine Targeting the Expression of Anti-Apoptotic Proteins by Antisense Oligonucleotides
Current Drug Targets Regulation of the DNA Damage Response to DSBs by Post-Translational Modifications
Current Genomics Fibroblast Growth Factor-Inducible 14: Multiple Roles in Tumor Metastasis
Current Molecular Medicine Role of Flavonoids in Future Anticancer Therapy by Eliminating the Cancer Stem Cells
Current Stem Cell Research & Therapy The HLA Region and Autoimmune Disease: Associations and Mechanisms of Action
Current Genomics